

Reference Data

3rd Quarter - Fiscal Year 2016
(April 1, 2016 to December 31, 2016)

Consolidated Earnings

• Consolidated Financial Data	P. 1
• Consolidated Balance Sheets	P. 2
• Consolidated P/L Statement	P. 3
• Consolidated Sales Breakdown by Segment/Category	P. 4
• Consolidated Operating Income by Segment	P. 4
• Consolidated Sales - Leading Brands of Self-Medication Operations	P. 5
• Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations	P. 6
• Capital Expenditure	P. 7
• Depreciation and Amortization	P. 7
• R&D Expenses	P. 7
• Results of Major Consolidated Subsidiaries	
♦ Taisho Pharmaceutical	P. 8
♦ Taisho Toyama Pharmaceutical	P. 8
♦ Biofermin Pharmaceutical	P. 8
• Major Subsidiaries and Affiliates	P. 9
• Prescription Pharmaceutical Operations: New Drug Development-Taisho Pharmaceutical	P.10
• Launch of New Products	P.11

Consolidated Financial Data

(Millions of yen)

	March 2016(FY2015)				March 2017(FY2016)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E (new)	Full year E (previous)
Net sales	69,212	145,984	224,978	290,135	69,431	141,007	216,431	281,500	285,000
(YOY%)	(+1.2%)	(+2.9%)	(+1.5%)	(-0.1%)	(+0.3%)	(-3.4%)	(-3.8%)	(-3.0%)	(-1.8%)
Self-Medication operations	43,602	92,094	138,782	180,722	43,012	90,457	138,160	181,900	185,400
Prescription Pharmaceutical operations	25,609	53,889	86,195	109,413	26,418	50,550	78,270	99,600	99,600
Gross profit*	42,464	89,106	136,387	176,813	44,409	90,333	138,365	178,900	181,500
Selling, general and administrative expenses	37,229	75,180	113,665	147,935	35,302	73,678	111,804	148,400	152,000
Research and development expenses	5,406	10,499	15,569	21,768	5,050	10,496	15,519	22,100	23,400
(% Sales)	(7.8%)	(7.2%)	(6.9%)	(7.5%)	(7.3%)	(7.4%)	(7.2%)	(7.9%)	(8.2%)
Advertising expenses	5,466	11,019	17,849	21,366	5,013	10,595	17,880	22,600	23,500
Sales promotion expenses	7,628	15,999	24,615	31,775	7,082	15,069	23,338	30,300	30,800
Personnel expenses	9,213	18,241	27,308	36,042	9,090	18,078	27,034	36,200	36,700
Operating income	5,234	13,925	22,722	28,878	9,106	16,655	26,560	30,500	29,500
(YOY%)	(-39.2%)	(-14.2%)	(-8.5%)	(-9.7%)	(+74.0%)	(+19.6%)	(+16.9%)	(+5.6%)	(+2.2%)
Ordinary income	7,493	17,680	29,097	36,775	10,422	19,129	31,376	36,500	36,500
(YOY%)	(-30.4%)	(-9.7%)	(-5.8%)	(-7.1%)	(+39.1%)	(+8.2%)	(+7.8%)	(-0.7%)	(-0.7%)
Profit attributable to owners of parent	4,686	11,281	18,705	22,473	6,945	13,499	23,670	27,500	24,000
(YOY%)	(-29.6%)	(-10.4%)	(-4.8%)	(-8.4%)	(+48.2%)	(+19.7%)	(+26.5%)	(+22.4%)	(+6.8%)
Comprehensive income	6,610	7,620	19,940	9,059	3,455	5,317	18,994	-	-
(YOY%)	(-37.3%)	(-58.6%)	(-37.2%)	(-81.1%)	(-47.7%)	(-30.2%)	(-4.7%)	-	-
Basic EPS (yen)	57.81	139.16	230.74	277.75	86.92	168.93	296.21	344.15	300.37
Diluted EPS (yen)	57.78	139.09	230.61	277.59	86.86	168.82	296.01	343.93	300.17
BPS (yen)	7,908.88	7,916.70	8,012.47	7,870.04	7,857.63	7,876.45	7,990.93	8,036.70	8,072.90
Dividend per share (yen)	-	50.00	-	100.00	-	50.00	-	110.00	110.00
Payout ratio	-	-	-	36.0%	-	-	-	32.0%	36.6%
Capital expenditure	1,057	2,910	5,150	8,967	2,453	4,262	5,040	8,500	8,500
Depreciation and amortization	2,716	5,483	8,260	11,117	2,529	5,099	7,732	10,800	10,800
Total assets	770,223	768,737	789,243	759,049	751,353	752,705	762,998	766,000	771,000
Shareholders' equity	654,801	655,911	664,019	643,127	642,439	644,393	653,919	657,000	660,000
Return on equity (%)**	-	-	-	3.5%	-	-	-	4.3%	3.8%
Return on assets (%)**	-	-	-	2.9%	-	-	-	3.6%	3.1%
Equity ratio (%)	83.2%	83.5%	82.3%	82.9%	83.6%	83.6%	83.7%	83.8%	83.7%
Overseas sales	7,720	15,886	22,217	29,901	6,836	13,769	20,361	27,420	29,020
Overseas sales ratio (% of total sales)	11.2%	10.9%	9.9%	10.3%	9.9%	9.8%	9.4%	9.7%	10.2%
Number of employees	6,710	6,637	6,598	6,517	6,596	6,515	6,486	-	-

* After provision/reversal of reserve for returned unsold goods

** Average of the beginning and year-end balance of shareholders' equity / total assets

<Reference>

•E=Estimates

•The full-year forecasts for the fiscal year ending March 31, 2017 were announced on October 31, 2016.

Consolidated Balance Sheets

(Millions of yen)

	End of FY2015		End of FY2016/3Q		change	
	(March 31, 16)	% total	(Dec. 31, 16)	% total		
(Assets)						
I Current assets:	319,670	42.1%	309,266	40.5%	-10,403	
Cash and deposits	172,142		169,548		-2,594	
Notes and accounts receivable-trade	75,243		90,029		+14,786	
Marketable securities	34,316		12,705		-21,610	Bond redemptions:-21,500
Inventories	26,638		25,206		-1,432	
Deferred tax assets	6,128		5,731		-396	
Other	5,201		6,045		+843	
II Fixed assets:	439,379	57.9%	453,732	59.5%	+14,353	
(1) Tangible fixed assets:	98,950	(13.0%)	97,367	(12.8%)	-1,582	
Buildings and structures	45,979		50,135		+4,156	Completion of Omiya Distribution Center 2
Machinery, equipment and vehicles	7,211		6,361		-849	
Land	37,473		37,451		-22	
Other	8,285		3,418		-4,866	
(2) Intangible fixed assets:	38,863	(5.1%)	33,496	(4.4%)	-5,366	
Goodwill	19,046		16,599		-2,447	
Sales rights	4,675		3,732		-942	
Trademarks	12,175		9,976		-2,199	
Software	2,419		2,669		+249	
Other	547		519		-27	
(3) Investments and other assets:	301,565	(39.7%)	322,867	(42.3%)	+21,302	
Investment securities	237,213		246,798		+9,585	
Shares of subsidiaries and affiliates	54,590		66,415		+11,824	Acquisition of shares of Duoc Hau Giang Pharmaceutical JSC
Net defined benefit assets	568		730		+161	
Deferred tax assets	7,869		7,595		-273	
Other	1,322		1,327		+4	
Total assets	759,049	100.0%	762,998	100.0%	+3,949	
(Liabilities)						
I Current liabilities:	66,646	8.8%	60,008	7.9%	-6,637	
Notes and accounts payable-trade	27,082		24,598		-2,484	
Accounts payable	16,753		13,845		-2,907	
Accrued income tax	5,746		4,255		-1,491	
Provision for bonuses	3,855		2,893		-961	
Other	13,207		14,415		+1,207	
II Long-term liabilities:	49,275	6.5%	49,070	6.4%	-204	
Net defined benefit liabilities	23,713		23,850		+136	
Deferred taxes liabilities	16,333		16,650		+317	
Other	9,228		8,569		-658	
Total liabilities	115,922	15.3%	109,079	14.3%	-6,842	
(Net assets)						
I Shareholders' equity	600,862	79.2%	616,493	80.8%	+15,630	
Common stock	30,000	4.0%	30,000	3.9%	-	
Capital surplus	15,271	2.0%	15,272	2.0%	+1	
Retained earnings	623,255	82.1%	638,927	83.7%	+15,672	Profit attributable to owners of parent:+23,670, Dividend on retained earnings: -7,997
Treasury stock	-67,664	-8.9%	-67,706	-8.9%	-42	
II Accumulated other comprehensive income	28,029	3.7%	22,041	2.9%	-5,988	
Valuation difference on securities	35,736	4.7%	37,609	4.9%	+1,872	
Deferred gains or losses on hedges	-0	-0.0%	0	0.0%	+1	
Foreign currency translation adjustment	507	0.1%	-7,876	-1.0%	-8,383	
Remeasurements of defined benefit plans	-8,213	-1.1%	-7,692	-1.0%	+521	
III Subscription rights to shares	357	0.0%	478	0.1%	+121	
IV Non-controlling interests	13,878	1.8%	14,906	2.0%	+1,028	
Total net assets	643,127	84.7%	653,919	85.7%	+10,792	
Total liabilities and net assets	759,049	100.0%	762,998	100.0%	+3,949	

Consolidated P/L Statement

(Millions of yen)

	End of FY2015		End of FY2016/3Q		change	
	(March 31, 16)	% total	(Dec. 31, 16)	% total		
Net sales	224,978	100.0%	216,431	100.0%	-8,546	
Cost of sales	88,013	39.1%	77,984	36.0%	-10,028	
Gross profit on sales	136,965	60.9%	138,446	64.0%	+1,481	
Provision for sales returns	577		81		-495	
Gross profit	136,387	60.6%	138,365	63.9%	+1,977	
Selling, general and administrative expenses	113,665	50.5%	111,804	51.7%	-1,861	
Research and development expenses	15,569		15,519		-50	
Advertising expenses	17,849		17,880		+30	
Sales promotion expenses	24,615		23,338		-1,277	
Personnel expenses	27,308		27,034		-274	
Other	28,321		28,032		-289	
Operating income	22,722	10.1%	26,560	12.3%	+3,838	
Non-operating income	6,487	2.8%	5,981	2.8%	-505	(Previous year) Equity in earnings of entities accounted for using equity method: +432
Non-operating expenses	111	0.0%	1,165	0.5%	+1,053	Equity in losses of entities accounted for using equity method: +325 Foreign exchange losses: +737
Ordinary income	29,097	12.9%	31,376	14.5%	+2,278	
Extraordinary gains	15	0.0%	3,723	1.7%	+3,707	Gain on sale of investment securities: +3,709
Extraordinary losses	112	0.0%	138	0.1%	+26	
Income before income taxes and minority interests	29,001	12.9%	34,961	16.2%	+5,959	
Income taxes	8,977	4.0%	9,859	4.6%	+882	
Profit	20,024	8.9%	25,101	11.6%	+5,077	
Profit attributable to non-controlling interests	1,318	0.6%	1,431	0.7%	+112	
Profit attributable to owners of parent	18,705	8.3%	23,670	10.9%	+4,965	

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2016(FY2015)				March 2017(FY2016)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year (new)	Full year (previous)
Self-Medication operations (YOY%)	43,602 (+5.9%)	92,094 (+4.6%)	138,782 (+2.9%)	180,722 (+2.5%)	43,012 (-1.4%)	90,457 (-1.8%)	138,160 (-0.4%)	181,900 (+0.7%)	185,400 (+2.6%)
Japan	35,145	74,717	114,464	148,125	35,560	75,344	115,723	152,000	153,800
Overseas	7,720	15,880	22,208	29,875	6,832	13,757	20,347	27,400	29,000
Other	736	1,496	2,108	2,721	620	1,355	2,090	2,500	2,600
Prescription Pharmaceutical operations (YOY%)	25,609 (-5.8%)	53,889 (+0.3%)	86,195 (-0.7%)	109,413 (-4.2%)	26,418 (+3.2%)	50,550 (-6.2%)	78,270 (-9.2%)	99,600 (-9.0%)	99,600 (-9.0%)
Ethical drugs	24,967	52,740	84,774	107,215	24,562	48,140	75,451	96,100	96,100
Other	642	1,149	1,421	2,197	1,856	2,410	2,819	3,500	3,500
Total	69,212	145,984	224,978	290,135	69,431	141,007	216,431	281,500	285,000

Consolidated Operating Income by Segment

(Millions of yen)

	March 2016(FY2015)				March 2017(FY2016)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year (new)	Full year (previous)
Self-Medication operations (YOY%)	6,067 (-15.1%)	14,530 (-5.0%)	21,103 (-8.3%)	28,393 (-8.6%)	7,022 (+15.7%)	15,203 (+4.6%)	22,744 (+7.8%)	29,300 (+3.2%)	29,600 (+4.2%)
Prescription Pharmaceutical operations (YOY%)	-537 (-)	36 (-97.6%)	2,591 (-4.3%)	1,755 (-15.5%)	2,496 (-)	2,272 (-)	4,981 (+92.2%)	2,700 (+53.8%)	1,300 (-26.0%)
Other* (YOY%)	-295 (-)	-641 (-)	-972 (-)	-1,271 (-)	-412 (-)	-820 (-)	-1,165 (-)	-1,500 (-)	-1,400 (-)
Total	5,234	13,925	22,722	28,878	9,106	16,655	26,560	30,500	29,500

* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of Yen)

	March 2016(FY2015)				March 2017(FY2016)						
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E (new)	YOY	Full year E (previous)
Japan	35.1	74.7	114.5	148.1	35.6	75.3	115.7	+1.1%	152.0	+2.6%	153.8
<i>Lipovitan</i> series	15.9	33.8	49.0	60.5	15.6	33.0	47.4	-3.2%	59.7	-1.3%	60.4
<i>Pabron</i> series	4.1	9.9	18.0	24.8	4.3	10.2	18.8	+4.6%	25.8	+4.2%	25.5
<i>RiUP</i> series	3.6	8.1	12.6	16.5	3.8	7.9	12.3	-2.7%	16.4	-1.2%	16.9
<i>Livita</i> series	1.0	1.9	2.9	3.9	0.9	1.9	2.9	-1.6%	3.9	-0.8%	4.0
GI treatment series	0.9	1.9	3.1	4.1	0.9	1.8	3.0	-3.3%	4.0	-2.3%	4.1
<i>VICKS</i> series	0.5	1.4	2.8	3.6	0.5	1.5	2.9	+0.5%	3.6	+1.4%	3.7
<i>NARON</i> series	0.9	1.8	2.8	3.7	0.9	1.7	2.6	-7.1%	3.5	-5.1%	3.6
<i>Colac</i> series	0.8	1.6	2.5	3.3	0.8	1.6	2.5	-0.1%	3.4	+1.3%	3.4
<i>ZENA</i> series	0.6	1.3	2.1	2.7	0.5	1.3	2.3	+8.0%	3.0	+12.0%	3.3
<i>Biofermin</i> series	1.8	3.6	5.3	7.5	2.0	4.2	6.7	+24.5%	8.2	+10.2%	8.2
Overseas	7.7	15.9	22.2	29.9	6.8	13.8	20.3	-8.4%	27.4	-8.3%	29.0
Energy drinks	2.5	5.4	7.9	10.3	2.5	4.9	7.2	-8.8%	9.4	-9.4%	9.7
OTC drugs	4.9	10.0	13.6	18.4	4.2	8.5	12.6	-7.5%	17.1	-7.0%	18.5
Others	0.7	1.5	2.1	2.7	0.6	1.4	2.1	-0.9%	2.5	-8.1%	2.6

(Rounded to the nearest hundred-million)

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2016(FY2015)				March 2017(FY2016)						
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E (new)	YOY	Full year E (previous)
<i>Lipovitan</i> series	15.9	33.8	49.0	60.5	15.6	33.0	47.4	-3.2%	59.7	-1.3%	60.4
<i>Lipovitan D</i>	10.2	21.9	31.6	38.6	10.2	21.4	30.5	-3.5%	37.9	-1.7%	38.6
Others	5.7	11.8	17.4	21.9	5.4	11.6	17.0	-2.6%	21.8	-0.5%	21.8
(100mL other <i>Lipovitan</i>)	3.6	7.6	11.0	13.9	3.5	7.4	10.8	-2.0%	13.9	-0.2%	14.0
(50mL other <i>Lipovitan</i>)	2.1	4.2	6.4	8.0	1.9	4.2	6.1	-3.7%	7.9	-1.0%	7.8

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations

(Billions of Yen)

	March 2016(FY2015)				March 2017(FY2016)						
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E (new)	YOY	Full year E (previous)
<i>Edirol</i>	4.4	9.6	15.2	19.8	5.8	11.3	17.5	+15.3%	22.7	+14.4%	22.4
<i>ZOSYN</i>	6.6	14.5	22.8	27.3	4.2	8.3	12.7	-44.3%	15.1	-44.7%	15.4
<i>Clarith</i>	2.5	5.2	9.2	12.0	2.2	4.0	7.2	-20.9%	9.4	-21.6%	9.8
<i>Bonviva</i>	1.1	2.4	3.7	4.9	1.7	3.1	4.6	+23.9%	6.0	+21.8%	6.6
<i>Palux</i>	1.6	3.2	4.9	6.2	1.5	2.8	4.2	-13.6%	5.3	-14.6%	5.1
<i>Geninax</i>	0.4	1.1	3.2	4.3	1.1	2.7	3.9	+22.7%	5.2	+21.3%	5.0
<i>OZEX</i>	1.4	2.7	4.8	5.9	1.1	2.2	4.1	-14.5%	5.1	-13.1%	4.6
<i>Biofermin</i>	0.9	1.7	2.6	3.6	1.0	2.0	3.0	+15.8%	4.0	+12.4%	3.8
<i>Lusefi</i>	0.5	0.5	0.7	0.9	0.5	1.5	2.1	+206.6%	2.8	+217.0%	2.6
<i>LOQOA</i>	-	-	-	0.4	0.3	0.5	1.1	-	1.8	+312.1%	1.8

(Rounded to the nearest hundred-million)

Consolidated: Capital Expenditure

(Millions of yen)

	March 2016(FY2015)				March 2017(FY2016)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E (new)	Full year E (previous)
Total capital expenditure	1,057	2,910	5,150	8,967	2,453	4,262	5,040	8,500	8,500
Taisho Pharmaceutical	826	2,416	4,174	7,324	2,268	3,668	4,343	6,700	6,700
Omiya Factory	201	491	682	868	28	372	481	1,000	1,000
Hanyu Factory	0	0	1	21	-	11	11	60	60
Okayama Factory	3	5	5	28	0	4	93	110	70
Research Center	30	315	381	1,053	134	381	509	950	950
Others	590	1,603	3,102	5,351	2,105	2,899	3,246	4,580	4,620
Other subsidiaries	230	494	976	1,642	185	593	696	1,800	1,800

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2016(FY2015)				March 2017(FY2016)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E (new)	Full year E (previous)
Depreciation and amortization	2,716	5,483	8,260	11,117	2,529	5,099	7,732	10,800	10,800
Cost of sales	947	1,895	2,847	3,823	851	1,670	2,524	3,700	3,700
SGA expenses	1,768	3,588	5,412	7,293	1,678	3,429	5,207	7,100	7,100

Consolidated: R&D Expenses

(Millions of yen)

	March 2016(FY2015)				March 2017(FY2016)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year E (new)	Full year E (previous)
Total R&D expenses	5,406	10,499	15,569	21,768	5,050	10,496	15,519	22,100	23,400
Self-Medication operations	1,210	2,524	3,725	5,497	1,320	2,825	4,104	5,700	6,200
Prescription Pharmaceutical operations	4,195	7,975	11,844	16,270	3,730	7,670	11,415	16,400	17,200

Results of Major Consolidated Subsidiaries

Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 2016(FY2015)				March 2017(FY2016)						
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E (new)	YOY	Full year E (previous)
Net Sales	46.6	98.4	152.5	198.4	49.2	101.6	156.4	+2.6%	205.3	+3.5%	207.3
Self-Medication	35.5	75.6	115.7	150.1	35.9	76.2	117.2	+1.3%	154.0	+2.6%	155.7
Prescription Pharmaceutical	11.1	22.9	36.8	48.3	13.4	25.4	39.2	+6.5%	51.3	+6.3%	51.6
Operating income	2.5	7.9	14.2	19.5	5.9	11.1	17.9	+26.1%	22.2	+13.9%	21.4
Ordinary income	5.6	12.2	18.7	24.3	6.6	13.8	20.9	+11.7%	25.5	+4.9%	25.6
Profit	4.5	9.5	14.2	17.8	5.2	10.5	16.0	+12.5%	19.6	+9.9%	19.7

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical

(Billions of Yen)

	March 2016(FY2015)				March 2017(FY2016)						
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E (new)	YOY	Full year E (previous)
Net Sales	25.0	52.7	84.8	107.2	24.6	48.1	75.5	-11.0%	96.1	-10.4%	96.1
Operating income	0.3	1.3	2.8	2.7	1.4	2.0	2.9	+4.9%	1.7	+0.5%	2.3
Ordinary income	0.3	1.3	2.8	2.7	1.4	2.0	3.0	+5.8%	-	+1.3%	2.3
Profit	0.1	0.7	1.7	1.4	0.9	1.3	1.9	+17.7%	-	+21.5%	1.5

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical are included in the consolidated results of Prescription Pharmaceutical operations.

Sales and earnings of Biofermin Pharmaceutical

(Billions of Yen)

	March 2016(FY2015)				March 2017(FY2016)						
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	3Q (4-12)	YOY	Full year E (new)	YOY	Full year E (previous)
Net Sales	2.7	5.4	7.2	9.7	2.6	5.1	8.1	+13.4%	10.3	+6.6%	10.3
Self-Medication	1.8	3.8	4.9	6.6	1.7	3.4	5.5	+11.2%	6.7	+1.7%	6.7
Prescription Pharmaceutical	0.8	1.6	2.2	3.1	0.8	1.7	2.6	+18.5%	3.6	+17.1%	3.6
Operating income	0.9	1.7	1.8	2.3	0.7	1.3	2.3	+23.9%	2.4	+3.2%	2.4
Ordinary income	0.9	1.7	1.9	2.3	0.8	1.3	2.3	+23.5%	2.4	+3.2%	2.4
Profit	0.6	1.2	1.3	1.6	0.5	0.9	1.6	+25.3%	1.7	+6.9%	1.7

(Rounded to the nearest hundred-million)

Major Subsidiaries and Affiliates

(As of December 31, 2016)

Company	Address	Capital	Business	Ownership
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 29,804,450	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co.,Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co.,Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co.,Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	64.0
Taisho Toyama Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 2,000,000	PD	70.3
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Taisho Pharmaceutical (Taiwan) Co.,Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co.,Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co.,Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 163,000	SMG	100.0
Osotspa Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.0
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,000	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
(2) Equity accounting method				
Toyama Chemical Co.,Ltd.	Tokyo, Japan	,000 Yen 10,000,000	PD	34.0
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.1
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 871,643,300	SMG	24.4

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

*Ownership: including the portion of indirect ownership

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of February 2, 2017

In Japan

Phase 2

TS-091 (Oral)

- < Application > Central disorders of hypersomnolence
- < Development > In-house

TS-152 (Injection)

- < Application > Rheumatoid arthritis
- < Development > In-license (Licensor: Ablynx)
- < Description > Anti-TNF(Tumor Necrosis Factor)- α antibody
- < Remarks > Generic name: Ozoralizumab

TS-141 (Oral)

- < Application > Childhood Attention-Deficit/Hyperactivity Disorder
- < Development > In-house

TS-133 (Topical)

- < Application > Alopecia
- < Development > In-house

Overseas

Phase 1

TS-071 (Oral)

- < Target disease > Type 2 diabetes
- < In-house/Licensed-in > In-house
- < Description > Sodium-glucose cotransporter 2 (SGLT2) inhibitor
- < Remarks > Generic name: Luseogliflozin Hydrate
In Japan: Launched on May 23, 2014 (Product name: Lusefi)

TS-121 (Oral)

- < Target disease > Depression
- < In-house/Licensed-in > In-house

TS-091 (Oral)

- < Target disease > Central disorders of hypersomnolence
- < In-house/Licensed-in > In-house

TS-134 (Oral)

- < Target disease > Schizophrenia
- < In-house/Licensed-in > In-house

Launch of New Products

As of February 2, 2017

Self-Medication Operations

Lipovitan D limited-edition Christmas bottles

- < Description > Lipovitan D limited-edition Christmas bottles proved highly popular in 2015. These products were relaunched featuring new seasonally designed bottles with endearing illustrations in two color options: gold and silver. Sold in a limited quantity, for a limited period only, via Taisho Pharmaceutical Direct, a mail order and direct sales service.
- < Launch > November 2016

Lipovitan D limited-edition Valentine bottles

- < Description > Lipovitan D limited-edition Valentine bottles, which were popular in 2015, have been relaunched featuring adorable new bottle designs. Sold at convenience stores, drug stores and supermarkets, as well as via Taisho Pharmaceutical Direct. Available in a limited quantity, for a limited period only.
- < Launch > January 2017

Claritin® EX

- < Description > The first switch OTC drug for the prescription pharmaceutical Claritin®. Claritin® EX is a non-drowsy allergic rhinitis treatment that effectively relieves symptoms with just one tablet taken once a day. Japanese actress Haruka Igawa has been chosen to star in the TV commercial for Claritin® EX.
- < Launch > January 2017

Tablets for People with Slightly Elevated Blood Pressure (Pill Type)

- < Description > Classified as foods with function claims, this product is for people with slightly elevated blood pressure*. It contains 90 µg per pill of piperine derived from long pepper as a functional substance. It is available in a pill-type formulation that can be easily taken anywhere with water. It is easy for people to continue using the product daily as only 1 pill needs to be taken once a day. Sold via Taisho Pharmaceutical Direct.
- * The phrase "People with slightly elevated blood pressure" refers to those with high-normal blood pressure (defined as having a systolic reading of between 130 mm Hg and 139 mm Hg or a diastolic reading of between 85 mm Hg and 89 mm Hg.)
- < Launch > January 2017